PTGS2 and neoplasm: Fortunately, some recent studies have finally demonstrated a specific uptake of radiolabeled COX-2 inhibitors in inflammatory lesions as well as in tumor xenografts and gave the proof of principle of successfully targeting COX-2 in vivo with radiotracers.